Jacobs Levy Equity Management Inc. Sells 16,139 Shares of Semler Scientific Inc. $SMLR

Key Points

• Jacobs Levy Equity Management Inc. has reduced its stake in Sembler Scientific Inc. by 38.5%, selling 16,139 shares and retaining 25,806 shares worth approximately $934,000.
• Other institutional investors have also modified their positions in Semler Scientific, with notable increases led by Nuveen Asset Management LLC, which boosted its stake by 396.9%.
• Semler Scientific recently posted earnings of $5.04 per share, surpassing estimates, and currently holds a consensus rating of "Buy" with a target price averaging $81.75.

Jacobs Levy Equity Management Inc. decreased its holdings in shares of Semler Scientific Inc. (NASDAQ:SMLR - Free Report) by 38.5% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,806 shares of the company's stock after selling 16,139 shares during the period. Jacobs Levy Equity Management Inc. owned 0.27% of Semler Scientific worth $934,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Cambridge Investment Research Advisors Inc. raised its position in Semler Scientific by 10.2% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 6,226 shares of the company's stock valued at $225,000 after purchasing an additional 576 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Semler Scientific by 49,133.3% during the 1st quarter. GAMMA Investing LLC now owns 7,385 shares of the company's stock valued at $267,000 after purchasing an additional 7,370 shares in the last quarter. Nuveen Asset Management LLC boosted its stake in shares of Semler Scientific by 396.9% during the 4th quarter. Nuveen Asset Management LLC now owns 124,548 shares of the company's stock valued at $6,726,000 after purchasing an additional 99,482 shares in the last quarter. Nuveen LLC bought a new stake in shares of Semler Scientific during the 1st quarter valued at about $990,000. Finally, Rhumbline Advisers boosted its stake in shares of Semler Scientific by 24.6% during the 1st quarter. Rhumbline Advisers now owns 7,418 shares of the company's stock valued at $269,000 after purchasing an additional 1,466 shares in the last quarter. Institutional investors own 49.37% of the company's stock.

Semler Scientific Stock Performance

Semler Scientific stock opened at $28.54 on Friday. The company has a quick ratio of 0.58, a current ratio of 0.60 and a debt-to-equity ratio of 0.25. The company has a market capitalization of $422.68 million, a P/E ratio of 11.74 and a beta of 1.39. The stock's 50 day moving average is $35.37 and its 200 day moving average is $35.99. Semler Scientific Inc. has a twelve month low of $21.77 and a twelve month high of $81.56.

Semler Scientific (NASDAQ:SMLR - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported $5.04 earnings per share for the quarter, topping the consensus estimate of ($0.27) by $5.31. The company had revenue of $8.22 million for the quarter, compared to the consensus estimate of $8.10 million. Semler Scientific had a return on equity of 43.84% and a net margin of 86.20%.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on SMLR. Maxim Group raised Semler Scientific to a "strong-buy" rating and set a $95.00 target price for the company in a research report on Wednesday, July 9th. Wall Street Zen lowered Semler Scientific from a "buy" rating to a "sell" rating in a research report on Thursday, May 22nd. Benchmark began coverage on Semler Scientific in a research report on Tuesday, July 8th. They issued a "buy" rating and a $101.00 target price for the company. Finally, Cantor Fitzgerald decreased their target price on Semler Scientific from $61.00 to $60.00 and set an "overweight" rating for the company in a research report on Wednesday, August 6th. One research analyst has rated the stock with a Strong Buy rating and three have assigned a Buy rating to the company's stock. According to data from MarketBeat, Semler Scientific currently has a consensus rating of "Buy" and a consensus target price of $81.75.

Semler Scientific Company Profile

Semler Scientific, Inc provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.